Cargando…
PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis
Metastatic melanoma treatment has drastically changed during the past decade with the advent of immunotherapy. We conducted a meta-analysis, to assess PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma. METHODS: The EMBASE, Medline via PubMed, Scopus, Cochrane...
Autores principales: | He, Runzhi, Zhao, Xiaoling, Liu, Jianmin, Zhou, Yajing, Zhang, Xiaochong, Cheng, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575742/ https://www.ncbi.nlm.nih.gov/pubmed/36254050 http://dx.doi.org/10.1097/MD.0000000000030561 |
Ejemplares similares
-
Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report
por: Langan, Ewan A., et al.
Publicado: (2021) -
Risk factors and predictive models for early death in patients with advanced melanoma: A population-based study
por: Li, Siru, et al.
Publicado: (2023) -
Meta-analysis of clinical risk factors of patients with systemic lupus erythematosus complicated with invasive fungal infection
por: Meng, Yang, et al.
Publicado: (2023) -
Quantitative Analysis of Immunohistochemistry in Melanoma Tumors
por: Lilyquist, Jenna, et al.
Publicado: (2017) -
Efficacy of a topical formulation containing MIA (Melanoma Inhibitory Activity) ‐ Inhibitory peptides in a case of recalcitrant vitiligo in combination with UV exposure
por: Hernandez Navarro, Sergi, et al.
Publicado: (2022)